Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04776629 · ClinicalTrials.gov registry record · Phase 2
A Proof-of-Activity Study With Orticumab in Subjects With Psoriasis and Cardiometabolic Risk Factors
A Phase 2 study, sponsored by Abcentra.
- Completed
- Registry status
- Phase 2
- Development phase
- 77
- Enrollment target
NCT04776629 is a Phase 2 study that has completed, run by Abcentra. The registered enrollment target is 77 participants.
The verdict
NCT04776629, a Phase 2 study, has completed, sponsored by Abcentra.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 77 participants
- Enrollment target
Study Summary
The primary purpose of this proof-of-activity, phase 2 trial is to evaluate the safety and activity of orticumab in subjects with moderate to severe psoriasis and cardiometabolic risk factors.
Interventions
- DRUG Placebo
- DRUG Orticumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2021-06-30 |
| Est. Completion | 2022-11-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04776629
The ClinicalTrials.gov registry entry for NCT04776629 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 77 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abcentra, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04776629 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04776629 about?
NCT04776629 is a clinical study titled "A Proof-of-Activity Study With Orticumab in Subjects With Psoriasis and Cardiometabolic Risk Factors". The primary purpose of this proof-of-activity, phase 2 trial is to evaluate the safety and activity of orticumab in subjects with moderate to severe psoriasis and cardiometabolic risk factors.
What is the current status of trial NCT04776629?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 77 participants. The study started on 2021-06-30. Estimated completion is 2022-11-11.
What interventions are being tested in trial NCT04776629?
The interventions under investigation include: Placebo (DRUG), Orticumab (DRUG).
Who is sponsoring clinical trial NCT04776629?
This trial is sponsored by Abcentra, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.